Originally published bySydney Morning Herald
Amplia Therapeutics is launching a new clinical trial of its protein inhibitor drug narmafotinib in ovarian cancer, partnering with research group ANZGOG.
🇦🇺
More news from AustraliaAustralia
OCEANIA
Related News
‘Feverish activity’ underway after charges ‘finally’ laid over illegal structures
1d ago
Ex-All Blacks coach exits Japan club with blunt swipe at referees
1d ago
Six signs Queen Street is on the comeback
1d ago
Father ‘wilfully blind’ in allowing Hells Angels son to store 450kg of meth in rental unit
2h ago
Fully electric Lexus TZ unveiled, will land in NZ next year
1d ago